Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2021-12-21 00:00:00 ET · period of report 2021-12-20 · accession 0001209191-21-070768 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-21 | 2021-12-20 | FATE | Dulac Edward J III | CFO | M - OptEx | $35.52 | +14.4K | 126.4K | +13% | +$512.8K |
| D | 2021-12-21 | 2021-12-20 | FATE | Dulac Edward J III | CFO | S - Sale+OE | $60.00 | -16.0K | 110.4K | -13% | -$958.6K |
| D | 2021-12-21 | 2021-12-20 | FATE | Dulac Edward J III | CFO | M - OptEx | $0.00 | -14.4K | 128.2K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-20 | M | A | 14,437 | $35.52 | 126,381 | D | — | — | |
| 2 | Common | Common Stock | 2021-12-20 | S | D | 15,977 | $60.00 | 110,404 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2021-12-20 | M | D | 14,437 | $0.00 | 128,238 | D | $35.52 · — to 2030-08-17 | 14,437 Common Stock | (F2) The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. |